China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Long-Term Capital Lease Obligation : ¥100 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co Long-Term Capital Lease Obligation?

China Resourcesnjiu Medical & Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥100 Mil.

China Resourcesnjiu Medical & Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (¥136 Mil) to Dec. 2023 (¥120 Mil) and declined from Dec. 2023 (¥120 Mil) to Mar. 2024 (¥100 Mil).

China Resourcesnjiu Medical & Pharmaceutical Co's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (¥89 Mil) to Dec. 2022 (¥106 Mil) and increased from Dec. 2022 (¥106 Mil) to Dec. 2023 (¥120 Mil).

China Resourcesnjiu Medical & Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co Long-Term Capital Lease Obligation Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

148.20

88.71

105.82

119.51

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															141.87	139.02	135.67	119.51	100.20

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

China Resourcesnjiu Medical & Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110

Website

http://www.999.com.cn

China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.

Executives

Yang Zhan Ao	Executives
	Independent director
Li De Ming	Supervisors
Lin Xi Ping	Supervisors
Fang Ming	Director
Mai Yi	Executives

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines